This Is MS Multiple Sclerosis Community: Knowledge & Support

The first drug to show signs of not just halting multiple sclerosis (MS), but actually reversing the nerve damage caused by the condition, has taken a significant step towards clinical approval.

The results of a phase III trial, presented on 22 October at the 5th Joint Triennial Congress of the European and Americas Committees for Treatment and Research in Multiple Sclerosis, in Amsterdam, found that 78% of patients treated with the monoclonal antibody alemtuzumab remained free from relapse after two years -- and half the relapse rate of one of the standard therapies, interferon beta-1a (marketed as Rebif, among other names).

However, alemtuzumab did not perform quite as well as it had in earlier trials. There was some evidence that it had reversed damage to nerves, but the result was not statistically significant, says Alasdair Coles, a neuroscientist at the University of Cambridge, UK, and the UK chief investigator of the Comparison of Alemtuzumab and Rebif Efficacy in Multiple Sclerosis (CARE-MS) I trial.... Read More - http://www.msrc.co.uk/index.cfm/fuseact ... ageid/1307

_________________
The Multiple Sclerosis Resource Centre

Squiffy's House of Fun - Laughter for Multiple Sclerosis

I wish it had done more for me and I continue to hope. I'm going for a third dose in April, 2012. I'm still walking but not so easily and now I'm having trouble with my hands. My signature is continually degrading. I now hunt-n-peck with my index fingers. Typing is not what it used to be and I'm a computer programmer...finger movement is kind of necessary. Texting on my iphone is getting harder also.

_________________
Marcia